Pramod Gaudel1, Ghulam Rehman Mohyuddin1, January Fields-Meehan1. 1. and are Hematology-Oncology Fellow Physicians, both in the Department of Internal Medicine at The University of Kansas Medical Center in Westwood. is an Attending Physician in the Department of Hematology and Medical Oncology at the Kansas City Veterans Affairs Medical Center in Missouri.
Abstract
BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis. First-line multikinase inhibitors like sorafenib and lenvatinib are poorly tolerated and have low response rates. Several clinical trials have shown tolerability and efficacy of immunotherapy in this setting. The objective of this retrospective study was to determine the outcomes of front-line nivolumab in a frail real-world population. OBSERVATIONS: In this retrospective study conducted between January 2016 and December 2019, 14 men (median age, 63.5 years; range, 58-72 years) with HCC received nivolumab as front-line systemic therapy. Only 2 patients had a response to immunotherapy (14.3%), of which 1 patient had a complete response (7.1%). The median progression-free survival was 4 months and median overall survival was 8 months. Incidence of grade 3 or higher toxicity was 35%. CONCLUSIONS: In our small, real-world cohort of patients receiving immunotherapy as front-line systemic treatment for HCC, outcomes were poor with front-line immunotherapy.
BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis. First-line multikinase inhibitors like sorafenib and lenvatinib are poorly tolerated and have low response rates. Several clinical trials have shown tolerability and efficacy of immunotherapy in this setting. The objective of this retrospective study was to determine the outcomes of front-line nivolumab in a frail real-world population. OBSERVATIONS: In this retrospective study conducted between January 2016 and December 2019, 14 men (median age, 63.5 years; range, 58-72 years) with HCC received nivolumab as front-line systemic therapy. Only 2 patients had a response to immunotherapy (14.3%), of which 1 patient had a complete response (7.1%). The median progression-free survival was 4 months and median overall survival was 8 months. Incidence of grade 3 or higher toxicity was 35%. CONCLUSIONS: In our small, real-world cohort of patients receiving immunotherapy as front-line systemic treatment for HCC, outcomes were poor with front-line immunotherapy.
Authors: Lesley Seymour; Jan Bogaerts; Andrea Perrone; Robert Ford; Lawrence H Schwartz; Sumithra Mandrekar; Nancy U Lin; Saskia Litière; Janet Dancey; Alice Chen; F Stephen Hodi; Patrick Therasse; Otto S Hoekstra; Lalitha K Shankar; Jedd D Wolchok; Marcus Ballinger; Caroline Caramella; Elisabeth G E de Vries Journal: Lancet Oncol Date: 2017-03-02 Impact factor: 41.316
Authors: Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii Cheng Journal: N Engl J Med Date: 2020-05-14 Impact factor: 91.245
Authors: Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo Journal: Lancet Oncol Date: 2018-06-03 Impact factor: 41.316
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Bernhard Scheiner; Martha M Kirstein; Florian Hucke; Fabian Finkelmeier; Kornelius Schulze; Johann von Felden; Sandra Koch; Philipp Schwabl; Jan B Hinrichs; Fredrik Waneck; Oliver Waidmann; Thomas Reiberger; Christian Müller; Wolfgang Sieghart; Michael Trauner; Arndt Weinmann; Henning Wege; Jörg Trojan; Markus Peck-Radosavljevic; Arndt Vogel; Matthias Pinter Journal: Aliment Pharmacol Ther Date: 2019-04-12 Impact factor: 8.171